Aktuellt
SENASTE
Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controlling inflammation through resolution rather than traditional antagonism. Its lead candidate, resomelagon, is undergoing a phase IIb trial in rheumatoid arthritis designed to optimize the probability of success, with full recruitment expected by Q4 2025. Strong results could spur a partnering deal in 2026, representing a large upside to the current share price.
LÄS MER
